Entropy Neurodynamics Limited · ASX:ENP
Entropy Neurodynamics — Tryptamine Therapeutics — Investor Presentation (July 2024)
28 slides from Entropy Neurodynamics's investor presentation, July 2024
Slide 1: Precision Psychedelic Therapy
Precision Psychedelic Therapy Corporate Presentation – July 2024 ASX : TYP This presentation has been authorised for release by the Board of Tryptamine Therapeutics Limited
Slide 2: Disclaimers
DISCLAIMERS The information contained in this presentation (the ÒPresentationÓ) has been prepared by Tryp Therapeutics Inc. (ÒTrypÓ or the ÒCompanyÓ) and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provi
Slide 3: A Precision Approach to Psychedelic Medicine
A Precision Approach to Psychedelic Medicine With a focus on solving: EATING DISORDERS & CHRONIC PAIN Corporate Presentation Ð July 2024 03
Slide 4: Investment Highlights
Investment Highlights Pioneering a precision approach to psychedelics, targeting precise drug blood levels in patients Transformative and commercially scalable intellectual property (IV-Infused Psilocin) • Addresses the critical limitations of oral dosing of psilocybin • Platform has broad applicabi
Slide 5: Corporate overview
Corporate overview Other Holders Top 20 Holders Remaining Snapshot: shareholders Top 20 ASX code: TYP Shares on issue: 1.089Bn Market capitalisation: $21.8m (at $0.02 per share) Cash at bank: ~$6.7m (as at 29 May 2024) Major shareholders (at 5 July 2024) Debt: Nil Dr. William James Garner 16.4% Citi
Slide 6: World class team with proven Leadership
World class team with proven Leadership JASON CARROLL JIM GILLIGAN, PH.D. JIM OÕNEILL PETER MOLLOY MICHAEL SILVERMAN, Chief Executive Officer Chief Scientific Officer Chief Financial Officer Chief Business Officer M.D. Over 25 years as an Chief Medical Officer A seasoned and successful Over 35 years
Slide 7: Accelerating Global Research in Psychedelic Medicine
Accelerating Global Research in Psychedelic Medicine • Research into the Neuroplastic benefits of Psilocybin is 8-fold higher today than any time in clinical history • However, clinical trials with intent to generate an approvable clinical dossier have been desperately lacking • With so many entrant
Slide 8: Corporate Presentation – July 2024
Investor presentation Ð July 2024 24 08 Corporate Presentation Ð July 2024
Slide 9: IV-infused Psilocin: A Precision Approach to Psychedelics
IV-infused Psilocin: A Precision Approach to Psychedelics IV-infused Psilocin Oral Psilocybin * Short treatment duration of 1-2 hours ~8-10 hours Quick onset of psychedelic state (approx. 15 minutes) 1-2 hours Precision targeting of drug blood levels in patients highly variable Quickly reversible in
Slide 10: Trial Pipeline
Trial Pipeline Current Next 12-18 months** TRP-8803 INDICATION PHASE 1* PHASE 2 BINGE EATING Proprietary DISORDER IV-infused FIBROMYALGIA synthetic psilocin IRRITABLE BOWEL SYNDROME TRP-8802 INDICATION IND CLEARED PHASE 2a PARTNER Oral, BINGE EATING synthetic DISORDER psilocybin FIBROMYALGIA sourced
Slide 11: TRP-8803: Healthy Human Volunteer Study (Australia)
TRP-8803: Healthy Human Volunteer Study (Australia) IV-Infused Psilocin • Reversible in emergency • Precision targeting of drug blood levels • IP protection • Fast onset time to psychedelic state (approx. 15 minutes) • Commercially scalable • Short duration of treatment (1-2 hours) • Enables clinica
Slide 12: Pilot Studies Using Oral Psilocybin
Pilot Studies Using Oral Psilocybin • A cost effective method for identifying safety and efficacy signals for new indications TRP-8802 - ORAL TRP-8803 - IV PSILOCYBIN • Access to a common and readily available generic PSILOCIN molecule for clinical trials now Pilot studies to identify • Earliest pos
Slide 13: IV-infused Psilocin: overcomes the limitations of oral psilocybin
IV-infused Psilocin: overcomes the limitations of oral psilocybin Limitations of orally administered psilocybin: • High patient variability in terms of drug blood levels (refer graphic) ⚬ Psilocybin is converted into psilocin, the psychoactive metabolite, in the body ⚬ Percent conversion varies for
Slide 14: Dosing Variability of Oral Psilocybin
Dosing Variability of Oral Psilocybin Blood concentrations of psilocin after single dose of 15mg, 25mg & 30mg psilocybin 28 Patients, 15mg psilocybin 22 Patients, 25mg psilocybin 30mg Psilocybin in 28 subjects Corporate Presentation Ð July 2024 14 Clin Pharma and Therapeutics, Volume: 113, Issue: 4,
Slide 15: Focus on conversion of 25mg psilocybin
Focus on ÒconversionÓ of 25mg psilocybin Cohort 3 - Upper Dose (3 patients) Therapeutic Zone Cohort 2 - Midpoint Dose (3 patients) Cohort 1 - Lower Dose (3 patients) Corporate Presentation Ð July 2024 15 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First publis
Slide 16: Focus on conversion of 25mg psilocybin
Focus on ÒconversionÓ of 25mg psilocybin Cohort 3 - Upper Dose (3 patients) Therapeutic Zone Cohort 2 - Midpoint Dose (3 patients) Cohort 1 - Lower Dose (3 patients) Corporate Presentation Ð July 2024 15 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First publis
Slide 17: Focus on conversion of 25mg psilocybin
Focus on ÒconversionÓ of 25mg psilocybin Cohort 3 - Upper Dose (3 patients) Therapeutic Zone Cohort 2 - Midpoint Dose (3 patients) Cohort 1 - Lower Dose (3 patients) Corporate Presentation Ð July 2024 15 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First publis
Slide 18: Binge Eating Disorder: Phase 2a clinical trial
Binge Eating Disorder: Phase 2a clinical trial ÒWe are very excited for the potential of TRYPÕs treatment. The potential impact on patientsÕ lives is that it would be life changing for them.Ó BINGE EATING DISORDER (BED) Jennifer Miller, MD, Professor, University of Florida, Principal Investigator Re
Slide 19: University of Florida Phase 2a Interim Analysis: reduction in binge eating
University of Florida Phase 2a Interim Analysis: Significant reduction in frequency & extent of binge eating (daily, 4 weeks) Corporate Presentation Ð July 2024 19
Slide 20: University of Florida Phase 2a Interim Analysis: durable effect
University of Florida Phase 2a Interim Analysis: Durable effect on binge eating episodes Corporate Presentation Ð July 2024 20
Slide 21: University of Florida Phase 2a Interim Analysis: HADS scores
University of Florida Phase 2a Interim Analysis: Significant fall in Hospital Anxiety & Depression Scores (HADS) HADS Anxiety Score HADS Depression Score Corporate Presentation Ð July 2024 21
Slide 22: Fibromyalgia: Phase 2a clinical trial
Fibromyalgia: Phase 2a clinical trial FIBROMYALGIA ÒExisting treatment options for fibromyalgia are Chronic condition causing widespread pain and fatigue often ineffective and show significant side effects. We are excited to be working with the team at Tryp Therapeutics, who have shown Many cases li
Slide 23: Irritable Bowl Syndrome: Phase 2a clinical trial
Irritable Bowl Syndrome: Phase 2a clinical trial IBS ÒThere is tremendous potential for the treatment of Chronic abdominal pain + altered bowel habits debilitating IBS and other disorders of gut-brain interaction by utilizing the combined Affects 10-15% worldwide (~790M people)*; leading cause of wo
Slide 24: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing, and specific disease indications • Filed a provisional patent in March 2021 (US 63/161,070) covering TRP-8803 (IV-infused Psilocin); converted to PCT filing Mar
Slide 25: Multiple Near-Term Milestones and Catalysts
Multiple Near-Term Milestones and Catalysts* Catalyst Timeframe Status Completion of Tryp Therapeutics Inc. acquisition H1 2024 ✔ $6.5m capital raise H1 2024 ✔ Recommencement of trading on ASX H1 2024 ✔ Appointments to strengthen Scientific Advisory Board H1 2024 ✔ Start of TRP-8803 Phase 1 trial (A
Slide 26: Psychedelic Market Landscape
Psychedelic Market Landscape Company Ticker Mkt cap (AUD) Compound Stage Indication(s) AbbVie Inc. NYSE: ABBV 414Bn Multiple Phase 1 / 2 completed Multiple Treatment resistant depression, Compass Pathways NASDAQ: CMPS $912m Psilocybin Phase 3 PTSD, Anorexia GH Research NASDAQ: CMPS 469.7m 5-MeO-DMT
Slide 27: Investment highlights
Investment highlights A Precision Approach to Psychedelic Medicine • IV-Infused Psilocin overcomes critical challenges of oral psilocybin dosing, providing significant competitive advantages • Transformative and commercially scalable intellectual property (IV-Infused Psilocin) • Potential beneficiar
Slide 28: Contact
Contact Jason Carroll Chief Executive Officer jcarroll@tryptherapeutics.com Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au Website: www.tryptherapeutics.com Socials: X (Twitter) @tryptherapeutic Corporate Presentation Ð July 2024 28
Tryptamine Therapeutics — Investor Presentation (July 2024) on 6ix